Introduction
One of the most common questions about Elysian Drops is why the formula uses sublingual oil delivery rather than capsules. It is a reasonable question. Capsules are the standard format for most supplements. They are familiar, convenient, and widely trusted.
The answer is pharmacological, not cosmetic. The format of delivery determines how much of an active compound actually reaches your bloodstream, and at what concentration. For botanical essential oils specifically, the difference between sublingual oil delivery and standard oral capsules is significant enough to affect whether the active compounds reach a therapeutically relevant concentration at all.
This article explains the mechanism, first-pass metabolism, sublingual absorption, and why oil-soluble botanical compounds behave differently from water-soluble ones, and references the published pharmacological literature that documents these differences.
What Happens When You Swallow a Capsule
When you swallow a capsule, it travels to the stomach where it begins to dissolve. The contents are released into the gastrointestinal tract and absorbed through the intestinal wall. From there, the absorbed compounds enter the portal vein and travel directly to the liver.
The liver is the body's primary metabolic organ. Its job is to process, neutralise, and break down compounds it identifies as foreign before they reach the systemic circulation. This process is called first-pass metabolism, or the first-pass effect. It is not a flaw in human physiology. It is a protective mechanism. But it has a specific consequence for supplements and pharmaceuticals taken orally: a significant portion of the active compounds is metabolised and deactivated before it ever reaches the bloodstream at a systemic level.
The extent of first-pass metabolism varies by compound. For some drugs, the liver removes a relatively small proportion of the dose. For others, it removes the majority. According to StatPearls, published by the National Institutes of Health, oral administration subjects compounds to both intestinal absorption and hepatic first-pass metabolism, which can significantly reduce the bioavailable dose, the portion that actually reaches systemic circulation, compared to routes of administration that bypass the liver.
This is well-established pharmaceutical science. It is why nitroglycerin for acute cardiac events is administered sublingually rather than swallowed: because first-pass metabolism would eliminate so much of the compound orally that the dose would be therapeutically insufficient for the rapid response required.
What Happens With Sublingual Oil Delivery
Sublingual administration means placing a compound under the tongue, where it is absorbed through the sublingual mucosa, the thin, non-keratinised tissue on the floor of the mouth that is densely supplied with capillaries.
The sublingual mucosa is non-keratinised, meaning it lacks the tough outer layer of skin that exists to keep things out. Compounds placed under the tongue can pass directly through this tissue and into the capillary network beneath it, entering the systemic bloodstream without travelling through the gastrointestinal tract and without passing through the liver's first-pass metabolism.
According to a review published in the Asian Journal of Pharmaceutical Research, sublingual administration produces a faster onset of action than orally ingested tablets, and the compounds absorbed through the sublingual blood vessels bypass the hepatic first-pass metabolic processes. The review notes that sublingual delivery results in better bioavailability for compounds that undergo extensive first-pass metabolism when swallowed.
The NIH Bookshelf (StatPearls) confirms this mechanism: compounds that bypass first-pass metabolism maintain a higher concentration in systemic circulation than equivalent doses administered orally, because the liver has not had the opportunity to metabolise a portion of the dose before it reaches the bloodstream.
The Bioavailability Difference: What the Numbers Show
The difference between sublingual and oral bioavailability has been documented in pharmaceutical research using compounds that undergo significant first-pass metabolism.
Research referencing data from pharmaceutical bioavailability studies, including research published in Pharmaceutical Research (Springer), compared the bioavailability of propranolol via oral versus sublingual administration using identical doses. The oral route produced approximately 25% bioavailability. The sublingual route produced approximately 63% bioavailability, the same compound, the same dose, delivered differently, producing 2.5 times more active compound reaching systemic circulation.
A 2024 PMC study documented a 4.35 times increase in total drug exposure (measured by area under the curve, or AUC) for sublingual versus oral administration of the same compound.
These are not marginal differences. They represent a fundamental pharmacokinetic distinction in how much of an active compound is available to the body depending on how it is administered.
It is important to note that the specific bioavailability figures vary by compound. Not every substance will show the same differential between sublingual and oral routes. The magnitude of the advantage depends on how extensively a given compound undergoes first-pass metabolism. Compounds that are heavily metabolised by the liver show the largest differential. Compounds that are poorly absorbed through the sublingual mucosa may show less benefit from sublingual delivery.
Why This Is Particularly Relevant for Botanical Essential Oils
Botanical essential oils, including peppermint oil, fennel oil, caraway oil, and ginger oil, are lipophilic compounds. Lipophilic means they dissolve in and are carried by fat or oil, not water. This chemical property has two relevant consequences for delivery format.
First, lipophilic compounds are poorly compatible with water-based dissolving processes. When essential oil compounds are placed inside capsules, they must first dissolve in the aqueous environment of the gut before they can be absorbed through the intestinal wall. The dissolution process can be inconsistent, depending on gastric pH, the presence of food, individual gut motility, and the specific galenic preparation of the capsule.
Second, lipophilic compounds are naturally carried by oil, which is exactly the environment they exist in when suspended in an organic oil base for sublingual delivery. An essential oil compound in an oil suspension placed under the tongue is already in its natural carrier medium. It does not need to dissolve. It can pass directly through the lipophilic sublingual mucosa into the capillary network underneath.
This is not a new concept. It is why carminative botanical compounds have historically been administered as oil-based preparations in traditional apothecary practice, not as dried powdered herb compressed into tablets. The traditional format was not arbitrary. It reflected centuries of empirical observation that oil-based preparations of these botanicals produced more consistent and more pronounced effects than water-based or solid preparations.
Modern pharmacokinetic research provides the mechanism that explains this historical observation: lipophilic compounds in an oil carrier, administered sublingually, bypass first-pass metabolism and are absorbed through a mucosal surface that is naturally compatible with lipophilic substances.
Capsules: The Practical Limitations
Beyond first-pass metabolism and bioavailability, standard capsules have additional practical limitations for essential oil compounds.
Enteric Coating Variability
Some capsule formulations use enteric coating to protect the contents from gastric acid and ensure release in the small intestine. The dissolution of enteric coatings depends on intestinal pH, which varies between individuals and is affected by food, stress, and gut motility. The timing and location of release is therefore inconsistent between individuals and between doses in the same individual.
Filler and Binder Requirements
Essential oils cannot be compressed into standard capsules without excipients, fillers, binders, flow agents, that add bulk and stability. These excipients do not contribute to the therapeutic effect and in some cases can affect absorption.
Absorption Window Dependency
Oral capsules depend on the small intestinal absorption window, the portion of the gut where most absorption occurs. Transit time through this window is variable and affected by meal size, gut motility, and individual physiology. A compound that passes through the absorption window too quickly may not be fully absorbed. A sublingual compound bypasses this dependency entirely.
A Note on Context and Individual Variation
It is important to be precise about what this evidence means and what it does not mean.
The bioavailability data referenced in this article comes primarily from pharmaceutical compounds studied in controlled conditions. The specific figures, 25% oral bioavailability versus 63% sublingual, apply to the specific compounds studied under those specific conditions. Extrapolating exact percentages to every botanical essential oil in every formulation would not be scientifically accurate.
What the evidence does establish, from multiple pharmacological sources and mechanistic research, is the direction and nature of the difference: sublingual delivery bypasses first-pass metabolism, provides faster onset of action, and produces higher bioavailability for lipophilic compounds that undergo significant hepatic metabolism. These are documented pharmacokinetic principles, not marketing claims.
For a botanical formula designed to support daily digestive function, the consistency and predictability of absorption matters as much as the dose. A sublingual oil suspension taken on an empty stomach every morning provides a consistent delivery mechanism that does not depend on gastric conditions, capsule dissolution, or intestinal transit timing.
That is why Elysian uses sublingual oil delivery. Not as a differentiating feature. As the pharmacologically appropriate format for these specific botanical compounds.
Summary
When you swallow a capsule containing botanical compounds, a portion of the active content is metabolised by the liver before it reaches systemic circulation. This is first-pass metabolism. The proportion metabolised depends on the compound, but for many lipophilic botanical compounds it is significant.
Sublingual delivery bypasses the gastrointestinal tract and the liver's first-pass metabolism. Compounds absorbed through the sublingual mucosa enter the bloodstream directly, producing higher bioavailability and faster onset than the equivalent oral dose.
Botanical essential oils are lipophilic. They are naturally carried by oil, not water. An oil-based sublingual preparation delivers them in the format that is most compatible with their chemical properties, through a mucosal surface that is naturally permeable to lipophilic substances.
This is established pharmacokinetic science. It is the reason sublingual administration is the clinical standard for compounds where bioavailability and onset speed are critical, and it is the reason Elysian is formulated as a sublingual oil rather than a capsule.
References
- StatPearls — Drug Bioavailability. National Institutes of Health Bookshelf. ncbi.nlm.nih.gov/books/NBK557852
- Bioavailability — ScienceDirect Topics. sciencedirect.com/topics/medicine-and-dentistry/drug-bioavailability
- Sublingual Tablets — An Updated Review. Asian Journal of Pharmaceutical Research. 2019;9(2). asianjpr.com
- A.I.M. Nutrition. What Is Sublingual Absorption? (And Why It Matters for Supplements). aim-nutrition.com
- Wikipedia — Bioavailability. en.wikipedia.org/wiki/Bioavailability
- Better Family — Sublingual vs. Oral Vitamins: Which is Better for Absorption? betterfamily.com/pages/sublingual-vs-oral
